All In Biotech

Drug Trial Radar · NCT00393679

Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children

Last checked: Nov 19, 2026Latest source record: Feb 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,112 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,112

Actual

Start

Jul 2007

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Lead sponsor
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Liverpool School of Tropical Medicine; East African Network for Monitoring Antimalarial Treatment; Centre Muraz; University of Calabar; Tropical Diseases Research Centre, Zambia; University Hospital Tuebingen; Albert Schweitzer Hospital; Uganda Malaria Surveillance Project; Mbarara University of Science and Technology; Ministry of Health, Rwanda; University of Barcelona; Centro de Investigacao em Saude de Manhica
First posted
Oct 30, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months, up to 59 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective is to compare the safety and efficacy of 4 artemisinin-based combinations (ACT) \[amodiaquine-artesunate (AQ+AS), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL) and chlorproguanil/dapsone plus artesunate\] for single and repeat treatments of uncomplicated malaria in children. Safety will be determined by registering adverse events and grading, laboratory, and vital signs evaluations. Their incidence will be compared between the different study arms. TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities. The leading EC approved the amendment on 2nd June 2008. TO BE NOTED: since the batches of the study drug DHAPQ expire at the end of October 2008, and because of the unavailability of a new batch of DHAPQ from the manufacturer, the recruitment in the DHAPQ arm had to be discontinued on 30th October 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.

Conditions

  • Fever
  • Malaria

Interventions

  • amodiaquine-artesunate (ASAQ)Drug

    A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg

  • dihydroartemisinin-piperaquine (DHAPQ)Drug

    DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.

  • artemether-lumefantrine (AL)Drug

    Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.

  • Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)Drug

    Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate. TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.Time frame: Day 28
  2. PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.Time frame: Day 28

Locations

8 sites in 7 countries. Site status is shown where the registry gives one.

  • Centre Muraz/IRSS

    Bobo-Dioulasso, Burkina Faso

  • Albert Schweitzer Hospital

    Lambaréné, Gabon

  • Manhiça Health Research Center

    Manhiça, Mozambique

  • Hospital

    Calabar, Nigeria

  • Mashshesha and Rukara

    Kigali, Rwanda

  • Jinja and Tororo

    Kampala, Uganda

  • Mbarara,

    Mbarara, Uganda

  • Tropical Diseases Research Centre, P O Box 71769,

    Ndola, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.